Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Oct 11;35(3):440-442.
doi: 10.46497/ArchRheumatol.2020.7541. eCollection 2020 Sep.

Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis

Kemal Erol  1 , Ragıp Ertaş  2
Affiliations
Case Reports

Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis

Kemal Erol et al. Arch Rheumatol. .

Abstract

Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis. In this article, we present the first case of a 45-year-old male patient with rheumatoid arthritis who developed psoriasiform lesions following treatment with tofacitinib, and highlight the possible pathogenetic mechanisms involved in such an occurrence.

Keywords: Paradoxical; psoriasis; rheumatoid arthritis; tofacitinib.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Figures

Figure 1
Figure 1. Lesions on patient’s arms.
Figure 2
Figure 2. Patient’s hand X-ray.
Figure 3
Figure 3. Pelvis anteroposterior X-ray.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Azevedo A, Torres T. Tofacitinib: A New Oral Therapy for Psoriasis. Clin Drug Investig. 2018;38:101–112. - PubMed
    1. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977. - PubMed
    1. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-a agents. Autoimmun Rev. 2014;13:15–19. - PubMed
    1. Kawalec P, Sladowska K, Malinowska-Lipien I, Brzostek T, Kózka M. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag. 2017;14:15–29. - PMC - PubMed
    1. Cinats A, Heck E, Robertson L. Janus kinase inhibitors: a review of their emerging applications in dermatology. Skin Therapy Lett. 2018;23:5–9. - PubMed

Publication types

LinkOut - more resources